• +1-646-491-9876
    • +91-20-67278686

    Search

    Hemophilia B - Pipeline Review, H1 2017

    Hemophilia B - Pipeline Review, H1 2017

    • Report Code ID: RW0001767485
    • Category Pharmaceuticals
    • No. of Pages 112
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Hemophilia B - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H1 2017, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape.

    Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the defective clotting factor.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hemophilia B - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hemophilia B (Hematological Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hemophilia B (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 9, 4, 2, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

    Hemophilia B (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Hemophilia B - Overview
    Hemophilia B - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Hemophilia B - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Hemophilia B - Companies Involved in Therapeutics Development
    Alnylam Pharmaceuticals Inc
    Amarna Therapeutics BV
    Bayer AG
    Bioverativ Inc
    Catalyst Biosciences Inc
    China Biologic Products Inc
    CSL Ltd
    Dimension Therapeutics Inc
    Genethon SA
    Green Cross Corp
    MolMed SpA
    Novo Nordisk A/S
    OPKO Biologics Ltd
    Pfizer Inc
    Pharming Group NV
    Promethera Biosciences SA
    RegenxBio Inc
    rEVO Biologics Inc
    Sangamo Therapeutics Inc
    Shire Plc
    Spark Therapeutics Inc
    UniQure NV
    Hemophilia B - Drug Profiles
    AMT-060 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BAX-335 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BAY-1093884 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BIVV-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CB-2679d - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cell Therapy for Hemophilia B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    coagulation factor IX (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    coagulation factor IX (recombinant) , pegylated - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    coagulation factor VIIa (recombinant) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    concizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CSL-689 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DTX-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fitusiran - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy for Hematological Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy for Hemophilia B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy for Hemophilia B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate Coagulation Factor IX for Hemophilia B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate Coagulation Factor IX for Hemophilia B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HepaStem - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LR-769 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    marzeptacog alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MG-1113A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MOD-5014 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PF-06741086 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Factor IX Replacement for Hemophilia B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Inhibit Coagulation Factor XIV for Hemophilia A and Hemophilia B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SB-FIX - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SPK-9001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SVF-VIIa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Hemophilia B - Dormant Projects
    Hemophilia B - Discontinued Products
    Hemophilia B - Product Development Milestones
    Featured News & Press Releases
    Apr 11, 2017: Key Milestone Reached in Catalyst's Subcutaneous Factor IX Program
    Mar 31, 2017: FDA posts briefing materials prior to Advisory Committee meeting for nonacog beta pegol, a long-acting factor IX for the treatment of haemophilia B
    Mar 30, 2017: Catalyst Biosciences Announces Emergence from Key Patent Opposition Period Supporting Marzeptacog Alfa (activated) , Catalyst's Lead Clinical Program
    Mar 28, 2017: Catalyst Biosciences Announces IND Approval in South Korea for Next-Generation Subcutaneous Factor IX Program
    Mar 23, 2017: Novo Nordisk Receives CHMP Positive opinion For Refixia
    Mar 02, 2017: Long-term safety and efficacy extension study data of Alprolix for haemophilia B published in Thrombosis and Haemostasis
    Feb 14, 2017: Catalyst Biosciences Highlights Hemophilia Clinical Development Plans at the 19th Annual BIO CEO & Investor Conference
    Feb 02, 2017: Long-term safety and efficacy data of extended half-life therapy Alprolix in children with haemophilia B published in The Lancet Haematology
    Feb 02, 2017: Alnylam Presents New Data on Fitusiran at EAHAD
    Feb 01, 2017: Catalyst Biosciences Announces Positive Preclinical Data of Subcutaneously Dosed Coagulation Factor IX at EAHAD Annual Congress
    Feb 01, 2017: Sobi and Bioverativ to reveal new long-term safety and efficacy data of Alprolix at EAHAD
    Feb 01, 2017: Catalyst Biosciences Announces Positive Preclinical Data of Subcutaneously Dosed Coagulation Factor VIIa at EAHAD Annual Congress
    Jan 26, 2017: Catalyst Biosciences Announces Presentation on investigational coagulation factor CB 2679d at the 2017 Congress of the European Association of Haemophilia and Allied Disorders
    Jan 26, 2017: Catalyst Biosciences Announces Data Presentation on Marzeptacog alfa at the 2017 Congress of the European Association of Haemophilia and Allied Disorders
    Jan 06, 2017: FDA Accepts For Review LFB's BLA For Its Recombinant Factor VII
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Hemophilia B, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Hemophilia B - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017
    Hemophilia B - Pipeline by Amarna Therapeutics BV, H1 2017
    Hemophilia B - Pipeline by Bayer AG, H1 2017
    Hemophilia B - Pipeline by Bioverativ Inc, H1 2017
    Hemophilia B - Pipeline by Catalyst Biosciences Inc, H1 2017
    Hemophilia B - Pipeline by China Biologic Products Inc, H1 2017
    Hemophilia B - Pipeline by CSL Ltd, H1 2017
    Hemophilia B - Pipeline by Dimension Therapeutics Inc, H1 2017
    Hemophilia B - Pipeline by Genethon SA, H1 2017
    Hemophilia B - Pipeline by Green Cross Corp, H1 2017
    Hemophilia B - Pipeline by MolMed SpA, H1 2017
    Hemophilia B - Pipeline by Novo Nordisk A/S, H1 2017
    Hemophilia B - Pipeline by OPKO Biologics Ltd, H1 2017
    Hemophilia B - Pipeline by Pfizer Inc, H1 2017
    Hemophilia B - Pipeline by Pharming Group NV, H1 2017
    Hemophilia B - Pipeline by Promethera Biosciences SA, H1 2017
    Hemophilia B - Pipeline by RegenxBio Inc, H1 2017
    Hemophilia B - Pipeline by rEVO Biologics Inc, H1 2017
    Hemophilia B - Pipeline by Sangamo Therapeutics Inc, H1 2017
    Hemophilia B - Pipeline by Shire Plc, H1 2017
    Hemophilia B - Pipeline by Spark Therapeutics Inc, H1 2017
    Hemophilia B - Pipeline by UniQure NV, H1 2017
    Hemophilia B - Dormant Projects, H1 2017
    Hemophilia B - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Hemophilia B, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Alnylam Pharmaceuticals Inc
    Amarna Therapeutics BV
    Bayer AG
    Bioverativ Inc
    Catalyst Biosciences Inc
    China Biologic Products Inc
    CSL Ltd
    Dimension Therapeutics Inc
    Genethon SA
    Green Cross Corp
    MolMed SpA
    Novo Nordisk A/S
    OPKO Biologics Ltd
    Pfizer Inc
    Pharming Group NV
    Promethera Biosciences SA
    RegenxBio Inc
    rEVO Biologics Inc
    Sangamo Therapeutics Inc
    Shire Plc
    Spark Therapeutics Inc
    UniQure NV

    Request for Sample

    Report Url http://www.reportsweb.com//hemophilia-b-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//hemophilia-b-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//hemophilia-b-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments